Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026
Tyra Biosciences (TYRA) will host a conference call and webcast on September 9, 2026 at 8:00 am ET to discuss initial clinical results from the SURF302 Phase 2 study of oral dabogratinib in intermediate risk non-muscle invasive bladder cancer (IR NMIBC).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tyra Biosciences (TYRA) will host a conference call and webcast on September 9, 2026 at 8:00 am ET to discuss initial clinical results from the SURF302 Phase 2 study of oral dabogratinib in intermediate risk non-muscle invasive bladder cancer (IR NMIBC).
Investors can access the live webcast and slides via the “For Investors” page on the company’s website, or register in advance for telephone participation. A replay will be available online for at least 90 days.
Details
News Market Reaction – TYRA
On Sep 4, the day this news came out, TYRA closed 15.25% above the previous close. Argus tracked a peak move of +14.1% during that session. Our momentum scanner recorded 40 alerts for this stock that day. Relative volume reached 10.7x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 4 session.
Key Figures
- Trial phase
- Phase 2
- SURF302 study
- Conference date
- September 9, 2026
- Initial clinical-results call
- Call time
- 8:00 am ET
- September 9, 2026
- Replay availability
- 90 days
- Minimum website archive period
Previous Conferences,clinical trial Reports
-
Conference call scheduled to present interim SURF301 Phase 1/2 clinical results
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
fgfr medical
nmibc medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call and Webcast Information
TYRA is hosting a conference call and webcast on September 9, 2026, at 8:00 am ET. Participants may access a live webcast of the call and the associated slide presentation on the "For Investors" page of the TYRA website at https://ir.tyra.bio. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 90 days.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. TYRA's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help TYRA design and predict which candidates may demonstrate the highest potency, selectivity and tolerability in the clinic. TYRA's expertise in FGFR biology has created a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. TYRA's lead precision medicine stemming from SNÅP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma. TYRA is based in Carlsbad, California. For more information, please visit www.tyra.bio and engage with TYRA on LinkedIn.
Contact
Amy Conrad
aconrad@tyra.bio
View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026-302870004.html
SOURCE Tyra Biosciences
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When is Tyra Biosciences (TYRA) holding the SURF302 Phase 2 results conference call?
The conference call and webcast to discuss initial results from the SURF302 Phase 2 study are scheduled for Wednesday, September 9, 2026 at 8:00 am ET. The company will review early clinical data for oral dabogratinib in IR NMIBC.
What study results will be discussed on Tyra Biosciences’ September 9, 2026 TYRA conference call?
The call will cover initial clinical results from the SURF302 Phase 2 study, which evaluates oral dabogratinib for patients with intermediate risk non-muscle invasive bladder cancer (IR NMIBC).
How can investors access the Tyra Biosciences (TYRA) SURF302 results webcast?
Investors can access a live webcast of the call and the associated slide presentation on the “For Investors” page of the Tyra Biosciences website at https://ir.tyra.bio.
How do I join the Tyra Biosciences (TYRA) SURF302 conference call by telephone?
To participate via telephone, investors must register in advance using the provided registration link. After registering, they receive a confirmation email containing the dial-in number, a unique passcode, and a registrant ID needed to access the call.
Will a replay of the Tyra Biosciences (TYRA) SURF302 Phase 2 results call be available?
Yes. A replay of the conference call and webcast will be archived on the company’s website for at least 90 days, allowing investors to review the presentation after the live event.